

HB4707



100TH GENERAL ASSEMBLY

State of Illinois

2017 and 2018

HB4707

by Rep. Sue Scherer

SYNOPSIS AS INTRODUCED:

225 ILCS 80/15.1	
720 ILCS 570/204	from Ch. 56 1/2, par. 1204
720 ILCS 570/206	from Ch. 56 1/2, par. 1206

Amends the Illinois Controlled Substances Act. Changes the classification of Hydrocodone from a Schedule II controlled substance to a Schedule I controlled substance. Amends the Illinois Optometric Practice Act of 1987 to make a conforming change.

LRB100 16559 RLC 31691 b

CORRECTIONAL
BUDGET AND
IMPACT NOTE ACT
MAY APPLY

A BILL FOR

1 AN ACT concerning criminal law.

2 **Be it enacted by the People of the State of Illinois,**
3 **represented in the General Assembly:**

4 Section 5. The Illinois Optometric Practice Act of 1987 is
5 amended by changing Section 15.1 as follows:

6 (225 ILCS 80/15.1)

7 (Section scheduled to be repealed on January 1, 2027)

8 Sec. 15.1. Diagnostic and therapeutic authority.

9 (a) For purposes of the Act, "ocular pharmaceutical agents"
10 means topical anesthetics, topical mydriatics, topical
11 cycloplegics, topical miotics and mydriatic reversing agents,
12 anti-infective agents, anti-allergy agents, anti-glaucoma
13 agents (except oral carbonic anhydrase inhibitors, which may be
14 prescribed only in a quantity sufficient to provide treatment
15 for up to 30 days), anti-inflammatory agents (except oral
16 steroids, which may be prescribed only in a quantity sufficient
17 to provide treatment for up to 7 days), over-the-counter
18 agents, analgesic agents, anti-dry eye agents, and agents for
19 the treatment of hypotrichosis.

20 (a-3) In addition to ocular pharmaceutical agents that fall
21 within the categories set forth in subsection (a) of this
22 Section, the Board may add a pharmaceutical agent approved by
23 the FDA or class of agents for the purpose of the diagnosis or

1 treatment of conditions of the eye and adnexa after
2 consideration of the agent's systemic effects, side effects,
3 and the use of the agent within the practice of optometry. The
4 Board shall consider requests for additional agents and make
5 recommendations within 90 days after the receipt of the
6 request.

7 Within 45 days after the Board's recommendation to the
8 Department of a pharmaceutical agent or class of agents, the
9 Department shall promulgate rules necessary to allow for the
10 prescribing or administering of the pharmaceutical agent or
11 class of agents under this Act.

12 (a-5) Ocular pharmaceutical agents administered by
13 injection may be used only for the treatment of anaphylaxis.

14 (a-10) Oral pharmaceutical agents may be prescribed for a
15 child under 5 years of age only in consultation with a
16 physician licensed to practice medicine in all its branches.

17 (a-15) The authority to prescribe a Schedule III, IV, or V
18 controlled substance shall include analgesic agents only in a
19 quantity sufficient to provide treatment for up to 72 hours.
20 The prescription of a Schedule II controlled substance is
21 prohibited, ~~except for Dihydrocodeinone (Hydrocodone) with one~~
22 ~~or more active, non-narcotic ingredients only in a quantity~~
23 ~~sufficient to provide treatment for up to 72 hours, and only if~~
24 ~~such formulations of Dihydrocodeinone are reclassified as~~
25 ~~Schedule II by federal regulation.~~

26 (b) A licensed optometrist may remove superficial foreign

1 bodies from the human eye and adnexa and may give orders for
2 patient care to a nurse or other health care provider licensed
3 to practice under Illinois law.

4 (c) An optometrist's license shall be revoked or suspended
5 by the Department upon recommendation of the Board based upon
6 either of the following causes:

7 (1) grave or repeated misuse of any ocular
8 pharmaceutical agent; and

9 (2) the use of any agent or procedure in the course of
10 optometric practice by an optometrist not properly
11 authorized under this Act.

12 (d) The Secretary of Financial and Professional Regulation
13 shall notify the Director of Public Health as to the categories
14 of ocular pharmaceutical agents permitted for use by an
15 optometrist. The Director of Public Health shall in turn notify
16 every licensed pharmacist in the State of the categories of
17 ocular pharmaceutical agents that can be utilized and
18 prescribed by an optometrist.

19 (Source: P.A. 98-1111, eff. 8-26-14; 99-909, eff. 1-1-17.)

20 Section 10. The Illinois Controlled Substances Act is
21 amended by changing Sections 204 and 206 as follows:

22 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)

23 Sec. 204. (a) The controlled substances listed in this
24 Section are included in Schedule I.

1 (b) Unless specifically excepted or unless listed in
2 another schedule, any of the following opiates, including their
3 isomers, esters, ethers, salts, and salts of isomers, esters,
4 and ethers, whenever the existence of such isomers, esters,
5 ethers and salts is possible within the specific chemical
6 designation:

7 (1) Acetylmethadol;

8 (1.1) Acetyl-alpha-methylfentanyl

9 (N-[1-(1-methyl-2-phenethyl)-

10 4-piperidinyl]-N-phenylacetamide);

11 (2) Allylprodine;

12 (3) Alphacetylmethadol, except

13 levo-alphacetylmethadol (also known as levo-alpha-
14 acetylmethadol, levomethadyl acetate, or LAAM);

15 (4) Alphameprodine;

16 (5) Alphamethadol;

17 (6) Alpha-methylfentanyl

18 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)

19 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-

20 propanilido) piperidine;

21 (6.1) Alpha-methylthiofentanyl

22 (N-[1-methyl-2-(2-thienyl)ethyl-

23 4-piperidinyl]-N-phenylpropanamide);

24 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);

25 (7.1) PEPAP

26 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);

- 1 (8) Benzethidine;
- 2 (9) Betacetylmethadol;
- 3 (9.1) Beta-hydroxyfentanyl
- 4 (N-[1-(2-hydroxy-2-phenethyl)-
- 5 4-piperidinyll]-N-phenylpropanamide);
- 6 (10) Betameprodine;
- 7 (11) Betamethadol;
- 8 (12) Betaprodine;
- 9 (13) Clonitazene;
- 10 (14) Dextromoramide;
- 11 (15) Diampromide;
- 12 (16) Diethylthiambutene;
- 13 (17) Difenoquin;
- 14 (18) Dimenoxadol;
- 15 (19) Dimepheptanol;
- 16 (20) Dimethylthiambutene;
- 17 (21) Dioxaphetylbutyrate;
- 18 (22) Dipipanone;
- 19 (23) Ethylmethylthiambutene;
- 20 (24) Etonitazene;
- 21 (25) Etoxadine;
- 22 (26) Furethidine;
- 23 (26.1) Hydrocodone;
- 24 (27) Hydroxypethidine;
- 25 (28) Ketobemidone;
- 26 (29) Levomoramide;

- 1 (30) Levophenacymorphan;
- 2 (31) 3-Methylfentanyl
- 3 (N-[3-methyl-1-(2-phenylethyl)-
- 4 4-piperidyl]-N-phenylpropanamide);
- 5 (31.1) 3-Methylthiofentanyl
- 6 (N-[(3-methyl-1-(2-thienyl)ethyl-
- 7 4-piperidinyl]-N-phenylpropanamide);
- 8 (32) Morpheridine;
- 9 (33) Noracymethadol;
- 10 (34) Norlevorphanol;
- 11 (35) Normethadone;
- 12 (36) Norpipanone;
- 13 (36.1) Para-fluorofentanyl
- 14 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
- 15 4-piperidinyl]propanamide);
- 16 (37) Phenadoxone;
- 17 (38) Phenampromide;
- 18 (39) Phenomorphan;
- 19 (40) Phenoperidine;
- 20 (41) Piritramide;
- 21 (42) Proheptazine;
- 22 (43) Properidine;
- 23 (44) Propiram;
- 24 (45) Racemoramide;
- 25 (45.1) Thiofentanyl
- 26 (N-phenyl-N-[1-(2-thienyl)ethyl-

- 1 4-piperidinyl]-propanamide);
- 2 (46) Tilidine;
- 3 (47) Trimeperidine;
- 4 (48) Beta-hydroxy-3-methylfentanyl (other name:
- 5 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
- 6 N-phenylpropanamide);
- 7 (49) Furanyl fentanyl (FU-F);
- 8 (50) Butyryl fentanyl;
- 9 (51) Valeryl fentanyl;
- 10 (52) Acetyl fentanyl;
- 11 (53) Beta-hydroxy-thiofentanyl;
- 12 (54) 3,4-dichloro-N-[2-
- 13 (dimethylamino)cyclohexyl]-N-
- 14 methylbenzamide (U-47700);
- 15 (55) 4-chloro-N-[1-[2-
- 16 (4-nitrophenyl)ethyl]-2-piperidinylidene]-
- 17 benzenesulfonamide (W-18);
- 18 (56) 4-chloro-N-[1-(2-phenylethyl)
- 19 -2-piperidinylidene]-benzenesulfonamide (W-15);
- 20 (57) acrylfentanyl (acryloylfentanyl).

21 (c) Unless specifically excepted or unless listed in

22 another schedule, any of the following opium derivatives, its

23 salts, isomers and salts of isomers, whenever the existence of

24 such salts, isomers and salts of isomers is possible within the

25 specific chemical designation:

- 26 (1) Acetorphine;

- 1 (2) Acetyldihydrocodeine;
- 2 (3) Benzylmorphine;
- 3 (4) Codeine methylbromide;
- 4 (5) Codeine-N-Oxide;
- 5 (6) Cyprenorphine;
- 6 (7) Desomorphine;
- 7 (8) Diacetyldihydromorphine (Dihydroheroin);
- 8 (9) Dihydromorphine;
- 9 (10) Drotebanol;
- 10 (11) Etorphine (except hydrochloride salt);
- 11 (12) Heroin;
- 12 (13) Hydromorphenol;
- 13 (14) Methyldesorphine;
- 14 (15) Methyldihydromorphine;
- 15 (16) Morphine methylbromide;
- 16 (17) Morphine methylsulfonate;
- 17 (18) Morphine-N-Oxide;
- 18 (19) Myrophine;
- 19 (20) Nicocodeine;
- 20 (21) Nicomorphine;
- 21 (22) Normorphine;
- 22 (23) Pholcodine;
- 23 (24) Thebacon.

24 (d) Unless specifically excepted or unless listed in
25 another schedule, any material, compound, mixture, or
26 preparation which contains any quantity of the following

1 hallucinogenic substances, or which contains any of its salts,
2 isomers and salts of isomers, whenever the existence of such
3 salts, isomers, and salts of isomers is possible within the
4 specific chemical designation (for the purposes of this
5 paragraph only, the term "isomer" includes the optical,
6 position and geometric isomers):

7 (1) 3,4-methylenedioxyamphetamine

8 (alpha-methyl, 3,4-methylenedioxyphenethylamine,
9 methylenedioxyamphetamine, MDA);

10 (1.1) Alpha-ethyltryptamine

11 (some trade or other names: etryptamine;
12 MONASE; alpha-ethyl-1H-indole-3-ethanamine;
13 3-(2-aminobutyl)indole; a-ET; and AET);

14 (2) 3,4-methylenedioxymethamphetamine (MDMA);

15 (2.1) 3,4-methylenedioxy-N-ethylamphetamine

16 (also known as: N-ethyl-alpha-methyl-
17 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
18 and MDEA);

19 (2.2) N-Benzylpiperazine (BZP);

20 (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);

21 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);

22 (4) 3,4,5-trimethoxyamphetamine (TMA);

23 (5) (Blank);

24 (6) Diethyltryptamine (DET);

25 (7) Dimethyltryptamine (DMT);

26 (7.1) 5-Methoxy-diallyltryptamine;

- 1 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
- 2 (9) Ibogaine (some trade and other names:
- 3 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
- 4 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
- 5 indole; Tabernanthe iboga);
- 6 (10) Lysergic acid diethylamide;
- 7 (10.1) Salvinorin A;
- 8 (10.5) Salvia divinorum (meaning all parts of the plant
- 9 presently classified botanically as Salvia divinorum,
- 10 whether growing or not, the seeds thereof, any extract from
- 11 any part of that plant, and every compound, manufacture,
- 12 salts, isomers, and salts of isomers whenever the existence
- 13 of such salts, isomers, and salts of isomers is possible
- 14 within the specific chemical designation, derivative,
- 15 mixture, or preparation of that plant, its seeds or
- 16 extracts);
- 17 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
- 18 (12) Peyote (meaning all parts of the plant presently
- 19 classified botanically as Lophophora williamsii Lemaire,
- 20 whether growing or not, the seeds thereof, any extract from
- 21 any part of that plant, and every compound, manufacture,
- 22 salts, derivative, mixture, or preparation of that plant,
- 23 its seeds or extracts);
- 24 (13) N-ethyl-3-piperidyl benzilate (JB 318);
- 25 (14) N-methyl-3-piperidyl benzilate;
- 26 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine

1 (also known as N-hydroxy-alpha-methyl-
2 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
3 (15) Parahexyl; some trade or other names:
4 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
5 dibenzo (b,d) pyran; Synhexyl;
6 (16) Psilocybin;
7 (17) Psilocyn;
8 (18) Alpha-methyltryptamine (AMT);
9 (19) 2,5-dimethoxyamphetamine
10 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
11 (20) 4-bromo-2,5-dimethoxyamphetamine
12 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
13 4-bromo-2,5-DMA);
14 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
15 Some trade or other names: 2-(4-bromo-
16 2,5-dimethoxyphenyl)-1-aminoethane;
17 alpha-desmethyl DOB, 2CB, Nexus;
18 (21) 4-methoxyamphetamine
19 (4-methoxy-alpha-methylphenethylamine;
20 paramethoxyamphetamine; PMA);
21 (22) (Blank);
22 (23) Ethylamine analog of phencyclidine.
23 Some trade or other names:
24 N-ethyl-1-phenylcyclohexylamine,
25 (1-phenylcyclohexyl) ethylamine,
26 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;

- 1 (24) Pyrrolidine analog of phencyclidine. Some trade
2 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
3 PHP;
- 4 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 5 (26) 2,5-dimethoxy-4-ethylamphetamine
6 (another name: DOET);
- 7 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
8 (another name: TCPy);
- 9 (28) (Blank);
- 10 (29) Thiophene analog of phencyclidine (some trade
11 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
12 2-thienyl analog of phencyclidine; TPCP; TCP);
- 13 (29.1) Benzothiophene analog of phencyclidine. Some
14 trade or other names: BTCP or benocyclidine;
- 15 (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
- 16 (30) Bufotenine (some trade or other names:
17 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
18 3-(2-dimethylaminoethyl)-5-indolol;
19 5-hydroxy-N,N-dimethyltryptamine;
20 N,N-dimethylserotonin; mappine);
- 21 (31) (Blank);
- 22 (32) (Blank);
- 23 (33) (Blank);
- 24 (34) (Blank);
- 25 (34.5) (Blank);
- 26 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-

1 (2-methyloctan-2-yl)-6a,7,
2 10,10a-tetrahydrobenzo[c]chromen-1-ol

3 Some trade or other names: HU-210;

4 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-
5 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
6 tetrahydrobenzo[c]chromen-1-ol, its isomers,
7 salts, and salts of isomers; Some trade or other
8 names: HU-210, Dexanabinol;

9 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
10 6,6-dimethyl-3-(2-methyloctan-2-yl)-
11 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol

12 Some trade or other names: HU-211;

13 (37) (Blank);

14 (38) (Blank);

15 (39) (Blank);

16 (40) (Blank);

17 (41) (Blank);

18 (42) Any compound structurally derived from
19 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane
20 by substitution at the nitrogen atom of the indole ring by
21 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
22 cycloalkylethyl, aryl halide, alkyl aryl halide,
23 1-(N-methyl-2-piperidinyl)methyl, or
24 2-(4-morpholinyl)ethyl whether or not further substituted
25 in the indole ring to any extent, whether or not
26 substituted in the naphthyl ring to any extent. Examples of

1 this structural class include, but are not limited to,
2 JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;

3 (43) Any compound structurally derived from
4 3-(1-naphthoyl)pyrrole by substitution at the nitrogen
5 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
6 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
7 halide, 1-(N-methyl-2-piperidinyl)methyl, or
8 2-(4-morpholinyl)ethyl, whether or not further substituted
9 in the pyrrole ring to any extent, whether or not
10 substituted in the naphthyl ring to any extent. Examples of
11 this structural class include, but are not limited to,
12 JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;

13 (44) Any compound structurally derived from
14 1-(1-naphthylmethyl)indene by substitution at the
15 3-position of the indene ring by alkyl, haloalkyl, alkenyl,
16 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
17 halide, 1-(N-methyl-2-piperidinyl)methyl, or
18 2-(4-morpholinyl)ethyl whether or not further substituted
19 in the indene ring to any extent, whether or not
20 substituted in the naphthyl ring to any extent. Examples of
21 this structural class include, but are not limited to,
22 JWH-176;

23 (45) Any compound structurally derived from
24 3-phenylacetylindole by substitution at the nitrogen atom
25 of the indole ring with alkyl, haloalkyl, alkenyl,
26 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl

1 halide, 1-(N-methyl-2-piperidinyl)methyl, or
2 2-(4-morpholinyl)ethyl, whether or not further substituted
3 in the indole ring to any extent, whether or not
4 substituted in the phenyl ring to any extent. Examples of
5 this structural class include, but are not limited to,
6 JWH-167, JWH-250, JWH-251, and RCS-8;

7 (46) Any compound structurally derived from
8 2-(3-hydroxycyclohexyl)phenol by substitution at the
9 5-position of the phenolic ring by alkyl, haloalkyl,
10 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
11 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
12 2-(4-morpholinyl)ethyl, whether or not substituted in the
13 cyclohexyl ring to any extent. Examples of this structural
14 class include, but are not limited to, CP 47, 497 and its
15 C8 homologue (cannabicyclohexanol);

16 (46.1) Any compound structurally derived from
17 3-(benzoyl) indole with substitution at the nitrogen atom
18 of the indole ring by an alkyl, haloalkyl, alkenyl,
19 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
20 halide, 1-(N-methyl-2-piperidinyl)methyl, or
21 2-(4-morpholinyl)ethyl group whether or not further
22 substituted in the indole ring to any extent and whether or
23 not substituted in the phenyl ring to any extent. Examples
24 of this structural class include, but are not limited to,
25 AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and
26 RCS-4;

1 (47) (Blank);

2 (48) (Blank);

3 (49) (Blank);

4 (50) (Blank);

5 (51) (Blank);

6 (52) (Blank);

7 (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine_.

8 Some trade or other names: 2C-T-7;

9 (53.1) 4-ethyl-2,5-dimethoxyphenethylamine_ Some trade
10 or other names: 2C-E;

11 (53.2) 2,5-dimethoxy-4-methylphenethylamine_ Some
12 trade or other names: 2C-D;

13 (53.3) 4-chloro-2,5-dimethoxyphenethylamine_ Some
14 trade or other names: 2C-C;

15 (53.4) 4-iodo-2,5-dimethoxyphenethylamine_ Some trade
16 or other names: 2C-I;

17 (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine_ Some
18 trade or other names: 2C-T-2;

19 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine_
20 Some trade or other names: 2C-T-4;

21 (53.7) 2,5-dimethoxyphenethylamine_ Some trade or
22 other names: 2C-H;

23 (53.8) 2,5-dimethoxy-4-nitrophenethylamine_ Some trade
24 or other names: 2C-N;

25 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine_ Some
26 trade or other names: 2C-P;

1 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine. Some
2 trade or other names: 2C-G;

3 (53.11) The N-(2-methoxybenzyl) derivative of any 2C
4 phenethylamine referred to in subparagraphs (20.1), (53),
5 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
6 (53.8), (53.9), and (53.10) including, but not limited to,
7 25I-NBOMe and 25C-NBOMe;

8 (54) 5-Methoxy-N,N-diisopropyltryptamine;

9 (55) (Blank);

10 (56) (Blank);

11 (57) (Blank);

12 (58) (Blank);

13 (59) 3-cyclopropoylindole with substitution at the
14 nitrogen atom of the indole ring by alkyl, haloalkyl,
15 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
16 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
17 2-(4-morpholinyl)ethyl, whether or not further substituted
18 on the indole ring to any extent, whether or not
19 substituted on the cyclopropyl ring to any extent:
20 including, but not limited to, XLR11, UR144, FUB-144;

21 (60) 3-adamantoylindole with substitution at the
22 nitrogen atom of the indole ring by alkyl, haloalkyl,
23 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
24 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
25 2-(4-morpholinyl)ethyl, whether or not further substituted
26 on the indole ring to any extent, whether or not

1 substituted on the adamantyl ring to any extent: including,
2 but not limited to, AB-001;

3 (61) N-(adamantyl)-indole-3-carboxamide with
4 substitution at the nitrogen atom of the indole ring by
5 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
6 cycloalkylethyl, aryl halide, alkyl aryl halide,
7 1-(N-methyl-2-piperidinyl)methyl, or
8 2-(4-morpholinyl)ethyl, whether or not further substituted
9 on the indole ring to any extent, whether or not
10 substituted on the adamantyl ring to any extent: including,
11 but not limited to, APICA/2NE-1, STS-135;

12 (62) N-(adamantyl)-indazole-3-carboxamide with
13 substitution at a nitrogen atom of the indazole ring by
14 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
15 cycloalkylethyl, aryl halide, alkyl aryl halide,
16 1-(N-methyl-2-piperidinyl)methyl, or
17 2-(4-morpholinyl)ethyl, whether or not further substituted
18 on the indazole ring to any extent, whether or not
19 substituted on the adamantyl ring to any extent: including,
20 but not limited to, AKB48, 5F-AKB48;

21 (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
22 with substitution at the nitrogen atom of the indole ring
23 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
24 cycloalkylethyl, aryl halide, alkyl aryl halide,
25 1-(N-methyl-2-piperidinyl)methyl, or
26 2-(4-morpholinyl)ethyl, whether or not further substituted

1 on the indole ring to any extent, whether or not
2 substituted on the quinoline ring to any extent: including,
3 but not limited to, PB22, 5F-PB22, FUB-PB-22;

4 (64) 3-(1-naphthoyl)indazole with substitution at the
5 nitrogen atom of the indazole ring by alkyl, haloalkyl,
6 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
7 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
8 2-(4-morpholinyl)ethyl, whether or not further substituted
9 on the indazole ring to any extent, whether or not
10 substituted on the naphthyl ring to any extent: including,
11 but not limited to, THJ-018, THJ-2201;

12 (65) 2-(1-naphthoyl)benzimidazole with substitution at
13 the nitrogen atom of the benzimidazole ring by alkyl,
14 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
15 aryl halide, alkyl aryl halide,
16 1-(N-methyl-2-piperidinyl)methyl, or
17 2-(4-morpholinyl)ethyl, whether or not further substituted
18 on the benzimidazole ring to any extent, whether or not
19 substituted on the naphthyl ring to any extent: including,
20 but not limited to, FUBIMINA;

21 (66) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
22 3-carboxamide with substitution on the nitrogen atom of the
23 indazole ring by alkyl, haloalkyl, alkenyl,
24 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
25 halide, 1-(N-methyl-2-piperidinyl)methyl, or
26 2-(4-morpholinyl)ethyl, whether or not further substituted

1 on the indazole ring to any extent: including, but not
2 limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;

3 (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
4 indazole-3-carboxamide with substitution on the nitrogen
5 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
6 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
7 halide, 1-(N-methyl-2-piperidinyl)methyl, or
8 2-(4-morpholinyl)ethyl, whether or not further substituted
9 on the indazole ring to any extent: including, but not
10 limited to, ADB-PINACA, ADB-FUBINACA;

11 (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
12 indole-3-carboxamide with substitution on the nitrogen
13 atom of the indole ring by alkyl, haloalkyl, alkenyl,
14 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
15 halide, 1-(N-methyl-2-piperidinyl)methyl, or
16 2-(4-morpholinyl)ethyl, whether or not further substituted
17 on the indole ring to any extent: including, but not
18 limited to, ADBICA, 5F-ADBICA;

19 (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
20 3-carboxamide with substitution on the nitrogen atom of the
21 indole ring by alkyl, haloalkyl, alkenyl,
22 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
23 halide, 1-(N-methyl-2-piperidinyl)methyl, or
24 2-(4-morpholinyl)ethyl, whether or not further substituted
25 on the indole ring to any extent: including, but not
26 limited to, ABICA, 5F-ABICA;

1 (70) Methyl 2-(1H-indazole-3-carboxamido)-3-
2 methylbutanoate with substitution on the nitrogen atom of
3 the indazole ring by alkyl, haloalkyl, alkenyl,
4 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
5 halide, 1-(N-methyl-2-piperidinyl)methyl, or
6 2-(4-morpholinyl)ethyl, whether or not further substituted
7 on the indazole ring to any extent: including, but not
8 limited to, AMB, 5F-AMB;

9 (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
10 dimethylbutanoate with substitution on the nitrogen atom
11 of the indazole ring by alkyl, haloalkyl, alkenyl,
12 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
13 halide, 1-(N-methyl-2-piperidinyl)methyl, or
14 2-(4-morpholinyl)ethyl, whether or not further substituted
15 on the indazole ring to any extent: including, but not
16 limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;

17 (72) Methyl 2-(1H-indole-3-carboxamido)-3-
18 methylbutanoate with substitution on the nitrogen atom of
19 the indole ring by alkyl, haloalkyl, alkenyl,
20 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
21 halide, 1-(N-methyl-2-piperidinyl)methyl, or
22 2-(4-morpholinyl)ethyl, whether or not further substituted
23 on the indazole ring to any extent: including, but not
24 limited to, MMB018, MMB2201, and AMB-CHMICA;

25 (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
26 dimethylbutanoate with substitution on the nitrogen atom

1 of the indole ring by alkyl, haloalkyl, alkenyl,
2 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
3 halide, 1-(N-methyl-2-piperidinyl)methyl, or
4 2-(4-morpholinyl)ethyl, whether or not further substituted
5 on the indazole ring to any extent: including, but not
6 limited to, MDMB-CHMICA;

7 (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
8 indazole-3-carboxamide with substitution on the nitrogen
9 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
10 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
11 halide, 1-(N-methyl-2-piperidinyl)methyl, or
12 2-(4-morpholinyl)ethyl, whether or not further substituted
13 on the indazole ring to any extent: including, but not
14 limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;

15 (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-
16 3-carboxamide with substitution on the nitrogen atom of the
17 indole ring by alkyl, haloalkyl, alkenyl,
18 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
19 halide, 1-(N-methyl-2-piperidinyl)methyl, or
20 2-(4-morpholinyl)ethyl, whether or not further substituted
21 on the indazole ring to any extent: including, but not
22 limited to, APP-PICA and 5-fluoro-APP-PICA;

23 (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
24 4-AcO-DMT;

25 (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
26 name 5-MeO-MIPT;

- 1 (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
2 (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
3 (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
4 (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
5 (4-HO-MiPT);
6 (82) Fluorophenylpiperazine;
7 (83) Methoxetamine;
8 (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
9 ethcathinone).

10 (e) Unless specifically excepted or unless listed in
11 another schedule, any material, compound, mixture, or
12 preparation which contains any quantity of the following
13 substances having a depressant effect on the central nervous
14 system, including its salts, isomers, and salts of isomers
15 whenever the existence of such salts, isomers, and salts of
16 isomers is possible within the specific chemical designation:

- 17 (1) mecloqualone;
18 (2) methaqualone; and
19 (3) gamma hydroxybutyric acid.

20 (f) Unless specifically excepted or unless listed in
21 another schedule, any material, compound, mixture, or
22 preparation which contains any quantity of the following
23 substances having a stimulant effect on the central nervous
24 system, including its salts, isomers, and salts of isomers:

- 25 (1) Fenethylamine;
26 (2) N-ethylamphetamine;

- 1 (3) Aminorex (some other names:
2 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
3 4-5-dihydro-5-phenyl-2-oxazolamine) and its
4 salts, optical isomers, and salts of optical isomers;
- 5 (4) Methcathinone (some other names:
6 2-methylamino-1-phenylpropan-1-one;
7 Ephedrone; 2-(methylamino)-propiofenone;
8 alpha-(methylamino)propiofenone; N-methylcathinone;
9 methcathinone; Monomethylpropion; UR 1431) and its
10 salts, optical isomers, and salts of optical isomers;
- 11 (5) Cathinone (some trade or other names:
12 2-aminopropiofenone; alpha-aminopropiofenone;
13 2-amino-1-phenyl-propanone; norephedrone);
- 14 (6) N,N-dimethylamphetamine (also known as:
15 N,N-alpha-trimethyl-benzeneethanamine;
16 N,N-alpha-trimethylphenethylamine);
- 17 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
18 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
- 19 (8) 3,4-Methylenedioxypropiofenone (MDPV);
- 20 (9) Halogenated amphetamines and
21 methamphetamines - any compound derived from either
22 amphetamine or methamphetamine through the substitution
23 of a halogen on the phenyl ring, including, but not
24 limited to, 2-fluoroamphetamine, 3-
25 fluoroamphetamine and 4-fluoroamphetamine;
- 26 (10) Aminopropylbenzofuran (APB):

1 including 4-(2-Aminopropyl) benzofuran, 5-
2 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
3 benzofuran, and 7-(2-Aminopropyl) benzofuran;

4 (11) Aminopropyl dihydrobenzofuran (APDB):
5 including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
6 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
7 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
8 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;

9 (12) Methylaminopropylbenzofuran

10 (MAPB): including 4-(2-methylaminopropyl)
11 benzofuran, 5-(2-methylaminopropyl)benzofuran,
12 6-(2-methylaminopropyl)benzofuran
13 and 7-(2-methylaminopropyl)benzofuran.

14 (g) Temporary listing of substances subject to emergency
15 scheduling. Any material, compound, mixture, or preparation
16 that contains any quantity of the following substances:

17 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
18 (benzylfentanyl), its optical isomers, isomers, salts, and
19 salts of isomers;

20 (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
21 phenylpropanamide (thenylfentanyl), its optical isomers,
22 salts, and salts of isomers.

23 (h) Synthetic cathinones. Unless specifically excepted,
24 any chemical compound which is not approved by the United
25 States Food and Drug Administration or, if approved, is not
26 dispensed or possessed in accordance with State or federal law,

1 not including bupropion, structurally derived from
2 2-aminopropan-1-one by substitution at the 1-position with
3 either phenyl, naphthyl, or thiophene ring systems, whether or
4 not the compound is further modified in one or more of the
5 following ways:

6 (1) by substitution in the ring system to any extent
7 with alkyl, alkylendioxy, alkoxy, haloalkyl, hydroxyl, or
8 halide substituents, whether or not further substituted in
9 the ring system by one or more other univalent
10 substituents. Examples of this class include, but are not
11 limited to, 3,4-Methylenedioxcathinone (bk-MDA);

12 (2) by substitution at the 3-position with an acyclic
13 alkyl substituent. Examples of this class include, but are
14 not limited to, 2-methylamino-1-phenylbutan-1-one
15 (buphedrone); or

16 (3) by substitution at the 2-amino nitrogen atom with
17 alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
18 inclusion of the 2-amino nitrogen atom in a cyclic
19 structure. Examples of this class include, but are not
20 limited to, Dimethylcathinone, Ethcathinone, and
21 a-Pyrrolidinopropiophenone (a-PPP).

22 (Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;
23 100-368, eff. 1-1-18; revised 10-5-17.)

24 (720 ILCS 570/206) (from Ch. 56 1/2, par. 1206)

25 Sec. 206. (a) The controlled substances listed in this

1 Section are included in Schedule II.

2 (b) Unless specifically excepted or unless listed in
3 another schedule, any of the following substances whether
4 produced directly or indirectly by extraction from substances
5 of vegetable origin, or independently by means of chemical
6 synthesis, or by combination of extraction and chemical
7 synthesis:

8 (1) Opium and opiates, and any salt, compound,
9 derivative or preparation of opium or opiate, excluding
10 apomorphine, dextrorphan, levopropoxyphene, nalbuphine,
11 nalmeffene, naloxone, and naltrexone, and their respective
12 salts, but including the following:

- 13 (i) Raw Opium;
14 (ii) Opium extracts;
15 (iii) Opium fluid extracts;
16 (iv) Powdered opium;
17 (v) Granulated opium;
18 (vi) Tincture of opium;
19 (vii) Codeine;
20 (viii) Ethylmorphine;
21 (ix) Etorphine Hydrochloride;
22 (x) (Blank); ~~Hydrocodone~~;
23 (xi) Hydromorphone;
24 (xii) Metopon;
25 (xiii) Morphine;
26 (xiii.5) 6-Monoacetylmorphine;

1 (xiv) Oxycodone;

2 (xv) Oxymorphone;

3 (xv.5) Tapentadol;

4 (xvi) Thebaine;

5 (xvii) Thebaine-derived butorphanol.

6 (xviii) Methorphan, except drug products
7 containing dextromethorphan that may be dispensed
8 pursuant to a prescription order of a practitioner and
9 are sold in compliance with the safety and labeling
10 standards as set forth by the United States Food and
11 Drug Administration, or drug products containing
12 dextromethorphan that are sold in solid, tablet,
13 liquid, capsule, powder, thin film, or gel form and
14 which are formulated, packaged, and sold in dosages and
15 concentrations for use as an over-the-counter drug
16 product. For the purposes of this Section,
17 "over-the-counter drug product" means a drug that is
18 available to consumers without a prescription and sold
19 in compliance with the safety and labeling standards as
20 set forth by the United States Food and Drug
21 Administration.

22 (2) Any salt, compound, isomer, derivative or
23 preparation thereof which is chemically equivalent or
24 identical with any of the substances referred to in
25 subparagraph (1), but not including the isoquinoline
26 alkaloids of opium;

1 (3) Opium poppy and poppy straw;

2 (4) Coca leaves and any salt, compound, isomer, salt of
3 an isomer, derivative, or preparation of coca leaves
4 including cocaine or ecgonine, and any salt, compound,
5 isomer, derivative, or preparation thereof which is
6 chemically equivalent or identical with any of these
7 substances, but not including decocainized coca leaves or
8 extractions of coca leaves which do not contain cocaine or
9 ecgonine (for the purpose of this paragraph, the term
10 "isomer" includes optical, positional and geometric
11 isomers);

12 (5) Concentrate of poppy straw (the crude extract of
13 poppy straw in either liquid, solid or powder form which
14 contains the phenanthrine alkaloids of the opium poppy).

15 (c) Unless specifically excepted or unless listed in
16 another schedule any of the following opiates, including their
17 isomers, esters, ethers, salts, and salts of isomers, whenever
18 the existence of these isomers, esters, ethers and salts is
19 possible within the specific chemical designation, dextrorphan
20 excepted:

21 (1) Alfentanil;

22 (1.1) Carfentanil;

23 (1.2) Thiafentanil;

24 (2) Alphaprodine;

25 (3) Anileridine;

26 (4) Bezitramide;

- 1 (5) Bulk Dextropropoxyphene (non-dosage forms);
- 2 (6) Dihydrocodeine;
- 3 (7) Diphenoxylate;
- 4 (8) Fentanyl;
- 5 (9) Sufentanil;
- 6 (9.5) Remifentanil;
- 7 (10) Isomethadone;
- 8 (11) (Blank);
- 9 (12) Levorphanol (Levorphan);
- 10 (13) Metazocine;
- 11 (14) Methadone;
- 12 (15) Methadone-Intermediate,
- 13 4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
- 14 (16) Moramide-Intermediate,
- 15 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
- 16 acid;
- 17 (17) Pethidine (meperidine);
- 18 (18) Pethidine-Intermediate-A,
- 19 4-cyano-1-methyl-4-phenylpiperidine;
- 20 (19) Pethidine-Intermediate-B,
- 21 ethyl-4-phenylpiperidine-4-carboxylate;
- 22 (20) Pethidine-Intermediate-C,
- 23 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 24 (21) Phenazocine;
- 25 (22) Piminodine;
- 26 (23) Racemethorphan;

1 (24) (Blank);

2 (25) Levo-alpha-acetylmethadol (some other names:
3 levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).

4 (d) Unless specifically excepted or unless listed in
5 another schedule, any material, compound, mixture, or
6 preparation which contains any quantity of the following
7 substances having a stimulant effect on the central nervous
8 system:

9 (1) Amphetamine, its salts, optical isomers, and salts
10 of its optical isomers;

11 (2) Methamphetamine, its salts, isomers, and salts of
12 its isomers;

13 (3) Phenmetrazine and its salts;

14 (4) Methylphenidate;

15 (5) Lisdexamfetamine.

16 (e) Unless specifically excepted or unless listed in
17 another schedule, any material, compound, mixture, or
18 preparation which contains any quantity of the following
19 substances having a depressant effect on the central nervous
20 system, including its salts, isomers, and salts of isomers
21 whenever the existence of such salts, isomers, and salts of
22 isomers is possible within the specific chemical designation:

23 (1) Amobarbital;

24 (2) Secobarbital;

25 (3) Pentobarbital;

26 (4) Pentazocine;

1 (5) Phencyclidine;

2 (6) Gluthethimide;

3 (7) (Blank).

4 (f) Unless specifically excepted or unless listed in
5 another schedule, any material, compound, mixture, or
6 preparation which contains any quantity of the following
7 substances:

8 (1) Immediate precursor to amphetamine and
9 methamphetamine:

10 (i) Phenylacetone

11 Some trade or other names: phenyl-2-propanone;

12 P2P; benzyl methyl ketone; methyl benzyl ketone.

13 (2) Immediate precursors to phencyclidine:

14 (i) 1-phenylcyclohexylamine;

15 (ii) 1-piperidinocyclohexanecarbonitrile (PCC).

16 (3) Nabilone.

17 (Source: P.A. 100-368, eff. 1-1-18.)